Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Ponatinib
Treatment for Chronic myeloid leukemia
Typical Dosage: 45 mg daily, often reduced to 15-30 mg daily
Effectiveness
93%
Safety Score
45%
Clinical Trials
43
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
45 mg daily, often reduced to 15-30 mg daily
Time to Effect
3-6 months for major response
Treatment Duration
Lifetime
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$3,500
Side Effect Mgmt:$5,000
Total Annual:$188,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
7
Outcome-Based Costs
Cost per Responder
$342,727
Cost per Remission
$538,571
Ponatinib Outcomes
for Chronic myeloid leukemia
Efficacy Outcomes
Overall Effectiveness
+93%
Response Rate
+55%
Remission Rate
+35%
Common Side Effects
Arterial occlusive events (AOEs)
+25%
Hypertension
+65%
Rash
+45%
Abdominal pain
+35%
Fatigue
+35%
Pancreatitis
+15%
Myelosuppression
+35%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
5 active trials recruiting for Ponatinib in Chronic myeloid leukemia
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
NCT04070443ACTIVE NOT RECRUITINGPHASE2
170 participants
INTERVENTIONAL
Amiens, France +27 more
Started: Nov 13, 2019
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372RECRUITINGPHASE1, PHASE2
70 participants
INTERVENTIONAL
Ghent, Belgium +22 more
Started: Jan 29, 2020
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346ACTIVE NOT RECRUITINGPHASE2
93 participants
INTERVENTIONAL
Hefei, China +13 more
Started: Jul 9, 2020
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT06390306RECRUITING
30 participants
OBSERVATIONAL
Beijing, China +14 more
Started: Jul 1, 2024
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT04188405ACTIVE NOT RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Houston, United States
Started: May 17, 2020
Completed Clinical Trials
5 completed trials for Ponatinib in Chronic myeloid leukemia
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
NCT05286528COMPLETED
1.48K participants
OBSERVATIONAL
Budapest, Hungary
Started: Nov 18, 2020
Genomics Study in CML Patients With Ponatinib Treatment
NCT06945146COMPLETED
65 participants
OBSERVATIONAL
Seoul, South Korea
Started: Sep 1, 2020
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
NCT00660920COMPLETEDPHASE1
81 participants
INTERVENTIONAL
San Francisco, United States +4 more
Started: Jun 1, 2008
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
NCT02467270COMPLETEDPHASE2
283 participants
INTERVENTIONAL
Atlanta, United States +85 more
Started: Jul 13, 2015
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01207440COMPLETEDPHASE2
449 participants
INTERVENTIONAL
St Leonards, Australia +41 more
Started: Sep 30, 2010
Showing 20 of 43 total trials